Aurinia Pharmaceuticals I... (AUPH)
NASDAQ: AUPH
· Real-Time Price · USD
12.02
-0.20 (-1.64%)
At close: Aug 19, 2025, 3:59 PM
12.05
0.25%
After-hours: Aug 19, 2025, 05:39 PM EDT
Company Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally.
The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.
The company is headquartered in Victoria, Canada.
Aurinia Pharmaceuticals Inc.
| Country | CA |
| IPO Date | Sep 3, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Peter S. Greenleaf |
Contact Details
Address: 4464 Markham Street Edmonton, BC CA | |
| Website | https://www.auriniapharma.com |
Stock Details
| Ticker Symbol | AUPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001600620 |
| CUSIP Number | 05156V102 |
| ISIN Number | CA05156V1022 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter S. Greenleaf M.B.A. | President, Chief Executive Officer & Director |
| Joseph M. Miller CPA | Chief Financial Officer |
| Andrea Levin Christopher | Executive Director of Corporate Communications & Investor Relations |
| Dr. Gregory F. Keenan M.D. | Chief Medical Officer |
| Dr. Premchandran Ramiya Ph.D. | Senior Vice President of Manufacturing & Supply Chain |
| Matthew Maxwell Donley M.B.A. | Chief Operations Officer |
| Stephen P. Robertson | Executive Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Aug 05, 2025 | 4 | Filing |
| Aug 05, 2025 | 4 | Filing |
| Jul 31, 2025 | 10-Q | Quarterly Report |
| Jul 31, 2025 | 8-K | Current Report |
| Jun 30, 2025 | 8-K | Current Report |
| May 16, 2025 | 4 | Filing |
| May 16, 2025 | 4 | Filing |
| May 16, 2025 | 4 | Filing |
| May 16, 2025 | 4 | Filing |